Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutic (NQ: HALO )

54.62 -0.13 (-0.24%)
Streaming Delayed Price Updated: 11:38 AM EDT, Jul 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 165,821
Open 54.64
Bid (Size) 54.56 (4)
Ask (Size) 54.64 (2)
Prev. Close 54.75
Today's Range 54.21 - 55.46
52wk Range 32.83 - 55.82
Shares Outstanding 142,334,900
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition
These biotech stocks have promising outlooks that will bring major fortune to investors. Buy before it is too late. 
Via InvestorPlace
NASDAQ:HALO is showing good growth, while it is not too expensive.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is not too expensive for the growth it is showing. 
Via Chartmill

Performance

YTD
+46.08%
+46.08%
1 Month
+9.99%
+9.99%
3 Month
+43.66%
+43.66%
6 Month
+51.55%
+51.55%
1 Year
+30.98%
+30.98%

More News

Read More
Biotech Arvinas Stock Earns 82 RS Rating
Via Investor's Business Daily
Denali Therapeutics Stock Gets Technical Rating Upgrade
Via Investor's Business Daily
What 13 Analyst Ratings Have To Say About Halozyme Therapeutics
Via Benzinga
3 Biotech Stocks to Buy Now: Q3 Edition
Via InvestorPlace
NASDAQ:HALO qualifies as a high growth stock and is consolidating.
Via Chartmill
NASDAQ:HALO Shows Potential for a Breakout.
Via Chartmill
Decoding 12 Analyst Evaluations For Halozyme Therapeutics
Via Benzinga
NASDAQ:HALO appears to be flying under the radar despite its strong fundamentals.
Via Chartmill
3 Highly Rated Biotech Stocks for Your July Buy List
Via InvestorPlace
3 Breakout Biotech Stocks on Track to Double by 2032
Via InvestorPlace
UroGen Pharma Stock Earns 91 RS Rating
Via Investor's Business Daily
Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation.
Via Chartmill
Sarepta Therapeutics Scores 90-Plus RS Rating On Muscular Dystrophy Approval
Via Investor's Business Daily
NASDAQ:HALO: a strong growth stock preparing for the next leg up?.
Via Chartmill
Arcellx Stock Earns Relative Strength Rating Upgrade
Via Investor's Business Daily
Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87
Via Investor's Business Daily
Don't overlook NASDAQ:HALO—it's a hidden gem with strong fundamentals and an attractive price tag.
Via Chartmill
The 3 Best Healthcare Stocks to Buy in June 2024
Via InvestorPlace
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
Via Investor's Business Daily
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade
Via Investor's Business Daily
Krystal Biotech Stock Sees RS Rating Jump To 91
Via Investor's Business Daily
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
Via Benzinga
Halozyme Therapeutics Scores RS Rating Jump To 91
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.